



**OOG Business Meeting
Saturday 6.10.2018 Nicce 11:30 am**

1. Welcome:

The Ophthalmic Oncology Group (OOG) Business Meeting convened at 11:30 and was chaired by the OOG Committee: Steven Heegaard (SH), Alexandre Moulin (AM), Robert Verdijk (RV), and Jean-Pierre Caujolle (JPC). The group welcomed everyone to the 55th. OOG Meeting.

2. Finances:

RV provided an overview of the OOG finances. The OOG current balances are positive and there was a benefice from the last congress organized in Sienna. Contributions to the International Council of Ophthalmology have been done.

It was insisted on the necessity for everyone to pay his membership. The number of members who forget to pay their membership seems to be increasing.

A list of paid members will be added to the new OOG website.

3. Candidate Members:

The following members were proposed for candidate membership :

- Aicha Mouatbi
- Sacha Nahow

4. Future meeting:

UNITED KINGDOM, LONDON, 2019:

The future OOG spring meeting in London which be held at St Bartholomew Hospital from April 11th-13th. Further details should appear later on the OOG website.

ISRAEL, TEL AVIV 2020

Future proposals:

As the number of participants was limited, it was decided to choose the locations for future meetings at the next Spring meeting

5. Collaborative studies:

G Luyten mentioned the *BAP1* germline mutation study that had already been presented by Dr Chau at the Rotterdam meeting in 2017. The study goal is to assess the association between the genotype and phenotype of *BAP1* germline mutations as well as the management guidelines for *BAP1* germline mutation carriers.

RV reminded his proposal for collaborative study on medulloepithelioma. He will be evaluating with Tero Kivela the clinicopathological features of medulloepithelioma aiming an improvement in the stratification of these tumors

6. AOB:

A long discussion was elaborated whether or not OOG should remain within EVER. The opinions were contrasted. The EVER board and some members felt that remaining in a general ophthalmology congress was a good idea combined to the fact that EVER is a European Research meeting. On the other hand, some members expressed the fact that EVER membership and registration is very expensive, possibly explaining the progressive decline of abstract submitted each year at the fall/ EVER meeting. It was also felt that attending a congress such EURETINA could be an opportunity to reach a much broader audience. OOG could be responsible for the organization of an oncology course. The idea of having only one OOG meeting / year was formulated and OOG participation to clinical meetings such as EURETINA with courses could be done in the fall. As the number of participants was limited, it was decided that this important issue for OGG should be discussed further at the next spring where a vote will be proposed to all members.

The participation of OOG to other meeting such a WOC and SOE was discussed. It was felt that the OOG board should be aware of the courses that are provided in the name of OOG.

The deadline of October 15th. or abstract submission for the next ISOO meeting in LA was reminded.